Retrospective study for significance of polymorphisms of UGT1A1 for Irinotecan toxicities in advanced cancer patients who received Irinotecan chemotherapy
Not Applicable
- Conditions
- advanced cancer
- Registration Number
- JPRN-UMIN000002884
- Lead Sponsor
- Tohoku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
n/a
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severe adverse effects of grade 3 or severer neutropenia and/or diarrhea after receiving Irinotecan containing chemotherapy
- Secondary Outcome Measures
Name Time Method